Aprea Therapeutics(APRE) - 2024 Q3 - Quarterly Results

Financial Position - As of September 30, 2024, the company expects cash and cash equivalents to be approximately $26.2 million, down from approximately$28.7 million as of June 30, 2024, representing a decrease of about 8.7%[4] - The preliminary cash and cash equivalents figure is subject to completion and may vary from the actual financial position as of September 30, 2024[5] Management Changes - The company announced the engagement of Dr. Phillipe Pultar as Senior Medical Advisor, while Dr. Nadeem Mirza will step down as Chief Medical Officer effective October 9, 2024[6]